Abstract
The effectiveness of domestic alpha 2-interferon preparation reaferon was studied in vivo and in vitro for eradication of pathological hemopoietic clone in chronic myeloid leukemia. Reaferon administration for 1-30 months produced cytogenetic remission in 7%, hematological remission in 21%, partial hematological remission in 36% of the patients. Reaferon is indicated in chronic myeloid leukemia without splenomegaly. In the disease progression reaferon is uneffective. Mechanism of reaferon therapeutic action comprises three components: a direct antiproliferative effect on hemopoietic precursor cells, activation of cellular immunity, an effect on stem cell microenvironment.
MeSH terms
-
Adult
-
Antigens, CD / blood
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Bone Marrow Examination
-
Chronic Disease
-
Drug Evaluation
-
Female
-
Humans
-
Hydroxyurea / administration & dosage
-
Interferon Type I / administration & dosage*
-
Interferon alpha-2
-
Interferon-alpha
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Male
-
Recombinant Proteins
-
Remission Induction
-
Statistics, Nonparametric
-
Time Factors
Substances
-
Antigens, CD
-
Antineoplastic Agents
-
Interferon Type I
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Hydroxyurea